These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 20870054

  • 1. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Fang F, Zheng M, Chen Z.
    Vaccine; 2010 Nov 10; 28(48):7690-8. PubMed ID: 20870054
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.
    J Med Virol; 2010 Jan 10; 82(1):128-37. PubMed ID: 19950232
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 9. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R, Guan Y, Yang Z, Chen J, Wang H, Chen Q, Sui Z, Fang F, Chen Z.
    Vaccine; 2010 Jan 08; 28(3):673-80. PubMed ID: 19892041
    [Abstract] [Full Text] [Related]

  • 10. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T.
    Vaccine; 2011 Oct 26; 29(46):8330-7. PubMed ID: 21911027
    [Abstract] [Full Text] [Related]

  • 11. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G, Du L, Xiao W, Sun S, Lin Y, Chen M, Kou Z, He Y, Lustigman S, Jiang S, Zheng BJ, Zhou Y.
    Vaccine; 2010 Oct 18; 28(44):7233-40. PubMed ID: 20732469
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H.
    Vaccine; 2009 Oct 23; 27(45):6276-9. PubMed ID: 19840660
    [Abstract] [Full Text] [Related]

  • 14. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M, Liu F, Shen Y, Wang S, Xu W, Fang F, Sun B, Xie Z, Chen Z.
    Hum Vaccin Immunother; 2015 Oct 23; 11(2):397-406. PubMed ID: 25607884
    [Abstract] [Full Text] [Related]

  • 15. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).
    Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R, Norley S.
    Vaccine; 2011 Feb 11; 29(8):1690-9. PubMed ID: 21195079
    [Abstract] [Full Text] [Related]

  • 16. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P, Hedenskog M, Alves D, Brytting M, Schröder U, Linde A, Lundkvist A.
    Vaccine; 2010 Sep 07; 28(39):6491-7. PubMed ID: 20637767
    [Abstract] [Full Text] [Related]

  • 17. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK, Tomar P, Sharma V, Dixit VK.
    Vaccine; 2011 Nov 08; 29(48):9026-37. PubMed ID: 21939718
    [Abstract] [Full Text] [Related]

  • 18. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
    Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, Wang H, Zhang R, Chen Z.
    Biochem Biophys Res Commun; 2006 May 19; 343(4):1124-31. PubMed ID: 16580631
    [Abstract] [Full Text] [Related]

  • 19. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
    Xie H, Liu TM, Lu X, Wu Z, Belser JA, Katz JM, Tumpey TM, Ye Z.
    J Infect Dis; 2009 Dec 15; 200(12):1874-83. PubMed ID: 19909080
    [Abstract] [Full Text] [Related]

  • 20. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
    Yang P, Tang C, Luo D, Zhan Z, Xing L, Duan Y, Jia W, Peng D, Liu X, Wang X.
    Vet Microbiol; 2010 Nov 20; 146(1-2):17-23. PubMed ID: 20888151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.